C5 Protein
Purified human C5 protein
Product Specifications
| Citations | 9 |
|---|---|
| Description |
Purified human C5 protein |
| Storage | Store at -70°C or below. Avoid freeze/thaw. |
| Form |
Frozen liquid. 10 mM sodium phosphate, 145 mM NaCl, pH 7.2. No preservative, 0.22 µm filtered. |
| Concentration | 1.0 mg/mL (refer to CoA for lot specific concentration) |
| Applications |
See citations and technical data sheet for application info. |
Ordering Information
| Catalog Number | A403 |
|---|---|
| Catalog Number (CE) | N/A |
| Size | 250 µL |
| Price (USD) | $335.00 |
| Price (EURO) | 300,00 € |
Contact us
| US Phone | +1 (858) 552 1100 |
|---|---|
| EU Phone | +353 (91) 412 474 |
| US Email | contact-us@quidelortho.com |
| EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
| Description |
Purified human C5 protein |
|---|---|
| Size | 250 µL |
| Storage |
Store at -70°C or below. Avoid freeze/thaw. |
| Form | Frozen liquid. 10 mM sodium phosphate, 145 mM NaCl, pH 7.2. No preservative, 0.22 µm filtered. |
| Concentration | 1.0 mg/mL (refer to CoA for lot specific concentration) |
| Applications | See citations and technical data sheet for application info. |
| Purity | >95% by SDS-PAGE |
| Source |
Normal human serum |
| Activity | >80% versus normal human serum standard. |
| Molecular Weight | 190,000 Da (2 chains) |
| Background |
Purified human complement component C5. Complement component C5 is unique to the terminal complement pathway. 190 kD C5 protein is comprised of two chains (α 115 kD; ß 75 kD) and is present in plasma at 70 mg/L. Activation of either complement pathway can generate a C5 convertase enzyme capable of cleaving C5 to C5a (a potent anaphylatoxin) and C5b. Together with the other proteins of the terminal pathway, C5b forms the membrane attack complex or MAC. |
Citations
| Title | Year | Applications | Sample Species | Sample | Sample Details |
|---|---|---|---|---|---|
|
C5a-C5AR1 axis as a potential trigger of the rupture of intracranial aneurysms |
2024 | Complement Digestion Assay |
Purified Protein |
Purified Protein |
Aneurysm |
| 2019 | ELISA |
Human |
Plasma |
Chronic Lymphocytic Leukemia |
|
| 2019 | ELISA |
Human |
Serum |
Chronic Lymphocytic Leukemia |
|
| 2011 | ELISA |
Human |
Peripheral blood mononuclear cells |
||
| 2015 | Microarray |
Human |
Whole Blood |
||
| 2018 | Silver Stain |
Human |
Purified protein |
B. lanceolatus venom incubated |
|
| 2021 | WB |
Human |
Purified protein |
||
| 2015 | Silver Stain |
Premolis semirufa (Caterpillar) |
Bristle Extract |
||
|
C5a–C5AR1 axis as a potential trigger of the rupture of intracranial aneurysms |
2024 | Complement Digestion Assay |
Purified Protein |
Purified Protein |
Aneurysm |
| 2013 | Silver Stain |
Snake |
Bothrops pirajai venom |
Certificate of Analysis
